The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Evolving treatment landscape for myeloma: ADCs
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the emergence of antibody-drug conjugates (ADC) as a new class of treatment for multiple myeloma, including belantamab mafodotin (belamaf) and belamaf-based combinations. There are also novel ADCs undergoing pre-clinical and early clinical trials, such as MEDI2228. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK
